Loading
A phase 2 trial of Lurbinectedin, Durvalumab in small-cell lung cancer, run by Jazz Pharmaceuticals, now recruiting.
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC is a phase 2 interventional study registered as NCT07459634 by Jazz Pharmaceuticals, with 50 participants planned, started 2026-11-30 and due to reach its primary completion in 2028-01-31. Interventions recorded: Lurbinectedin, Durvalumab. Conditions listed: Extensive-stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Lurbinectedin, Jazz Pharmaceuticals, Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Lurbinectedin, Jazz Pharmaceuticals, Cytotoxic chemotherapy.
Shares Lurbinectedin, Extensive-stage small-cell lung cancer, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Durvalumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Durvalumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Lurbinectedin, Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Extensive-stage small-cell lung cancer, Durvalumab, Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Lurbinectedin, Extensive-stage small-cell lung cancer, Small-cell lung cancer, Immune checkpoint inhibitors.